Who makes Morphine, memantine?

Morphine, memantine is developed by Helsinki University Central Hospital.

What development phase is Morphine, memantine in?

Morphine, memantine is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Morphine, memantine

Helsinki University Central Hospital · FDA-approved active Small molecule Quality 0/100

Morphine, marketed by Helsinki University Central Hospital, is a well-established analgesic with a key composition patent expiring in 2028. The drug's primary strength lies in its long-standing use and recognized efficacy for pain management. The primary risk is the potential increase in generic competition following the 2028 patent expiry.

At a glance

Generic name	Morphine, memantine
Also known as	Depolan (morphine), Ebixa (memantine)
Sponsor	Helsinki University Central Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Morphine, memantine CI brief — competitive landscape report
Morphine, memantine updates RSS · CI watch RSS
Helsinki University Central Hospital portfolio CI